Biologics Safety Testing Market

CHARLES RIVER LABRATORIES (US), LONZA (SWITZERLAND) and THERMO FISCHER SCIENTIFIC (US) are the Key Players in the Biologics Safety Testing Market

The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.

Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), and Eurofins Scientific (Luxembourg). The key players in this market are focusing on strategic expansions, partnerships, and product launches and approvals to expand their presence in the market.

To know about the assumptions considered for the study download the pdf brochure

CHARLES RIVER LABRATORIES (US)

Charles River is one of the key players in the biologics safety testing market, it is a service and early-stage contract research organization (CRO). The company develops a diverse portfolio of discovery and safety assessment services and provides a suite of products and services to support its clients’ manufacturing activities. The company operates through three reporting segments, namely, Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The company offers biologics safety testing solutions through its Manufacturing segment.

To further strengthen its market position, Charles River Laboratories focuses on expanding its service and product offerings in the biologics safety testing segment. The company offers customized assays to address specific concerns and needs, ensuring that an appropriate testing plan is designed for biological products. Fast Track Testing is also available for the quick delivery of urgently needed results. To maintain its leading position and enhance its market share, the company mainly focuses on exceeding customer expectations by maintaining the quality of its services and quickly adapting to new conditions with efficiency. The acquisitions of JADE Biomedical (China) and Cognate BioServices (US) strengthened the company’s portfolio and geographic presence in the market

LONZA (SWITZERLAND)

Lonza is a key player in the biologics safety testing market. The company has a large number of manufacturing and R&D facilities across the globe. With its wide geographic presence and high production capacity, the company delivers quality products across the globe. This has helped the company to develop new and advanced products. To maintain its position in the biologics safety testing market, the company focuses on organic growth strategies. In line with this, in April 2021, Lonza launched the PyroTec PRO Automated Robotic Solution, which is designed for use with the sustainable PyroGene Recombinant Factor C (rFC) Assay for endotoxin testing. Such developments have helped the company to enhance its visibility in the biologics safety testing market.

THERMO FISCHER SCIENTIFIC (US)

Thermo Fisher Scientific offers analytical instruments, equipment, reagents, and consumables for research, discovery, analysis, diagnostics, and manufacturing. The company operates through four principal product segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company offers a wide array of biologics safety testing products through its Life Sciences Solutions segment. The company offers wide range of biological safety testing kits for Endotoxin Testing, Residual Host-cell Proteins & DNA Detection Tests, Mycoplasma Tests, and Virus Safety Testing for biologics molecules.

Related Reports:

Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test) - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 3334
RI Published ON
5/10/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biologics Safety Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved